Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.44 |
| ▸ | KLK1 | P06870 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1823297 | 0.93 | CA12 (0.47) | CA12CA1CA2CA9CA4 | |
| SCHEMBL1823683 | 0.92 | CA12 (0.47) | CA12CA1CA2CA9CA4 | |
| SCHEMBL1820827 | 0.90 | CA12 (0.45) | CA12CA1CA2CA9CA4 | |
| SCHEMBL1823807 | 0.89 | CA12 (0.45) | CA12CA1CA2CA9CA4 | |
| SCHEMBL2403781 | 0.87 | CA12 (0.46) | CA12CA1CA2CA9CA4 | |
| SCHEMBL12319356 | 0.87 | CA1 (0.46) | CA12CA1CA2CA9CA4 | |
| SCHEMBL1817885 | 0.86 | KLK5 (0.48) | CA12CA1CA2CA9KLK5 | |
| SCHEMBL1826376 | 0.84 | CA1 (0.52) | CA12CA1CA2CA9CA4 | |
| SCHEMBL1821548 | 0.83 | CA12 (0.46) | CA12CA1CA2CA9CA4 | |
| SCHEMBL1824930 | 0.82 | CA1 (0.51) | CA12CA1CA2CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2011060199-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BCL6, BTD | LTA4H 1742/4885CA12 564/4885CA1 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.